CATALYST PHARMACEUTICALS, INC.CPRX

時価総額

$28.4億

PER

希少疾患向け医薬品の有力企業。FIRDAPSEやAGAMREEなど治療薬を展開。2023年10月のNDA承認と同年Q4の3600万ドル支払い。米国・カナダ中心に展開。

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	-	-	-	-	-	-	-	-34,003,514	32	75	39	83	71	164
Depreciation	-	-	-	26,574	34,468	43,406	45,689	37,978	54,327	92,065	0	0	0	0
Stock-based compensation	6	6	6	777,969	2	2	2	4	4	6	6	8	14	22
Amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	1	33	37
Deferred taxes	-	-	-	-	-	-	-	-	-	33	-9	-5	18	9
Accretion of discount	-	-	-	-	-	-	-	-	-	-	-	-	-1	1
Non cash change in right of use asset	-	-	-	-	-	-	-	-	243,399	793,252	0	0	0	0
Debt Securities, Available-for-Sale, Realized Loss	-	-	-	-	-	-	-	-	-	-	-	1	-	-
Acquired inventory samples expensed from asset acquisition	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Acquired in-process research and development	-	-	-	-	-	-	-	-	-	-	-	-	82	-
Change in fair value of equity securities	-	-	-	-	-	-	-	-	-	-	-	-	3	5
Accounts receivable, net	-	-	-	-	-	-	-	-	11	-4,549,571	1	4	43	12
Inventory	-	-	-	-	-	-	-	56,012	2	3	3	-1	5	4
Prepaid expenses and other current assets	208,004	1	2	3	452,040	-456,794	125,800	476,037	3	4	-4	1	6	9
Accounts payable	263,934	1	850,789	963,421	-20,083	-860,951	1	391,792	2	138,573	-1	1	11	2
Accrued expenses and other liabilities	516,033	239,528	1	3	1	-480,248	1	5	13	-1,209,280	6	16	6	54
Operating lease liability	-	-	-	-	-	-	-	-	276,807	919,280	1	-0	-0	-0
Net cash provided by (used in) operating activities	-4,985,049	-5,140,366	-9,875,674	-	-	-	-	-25,704,406	35	45	60	116	144	240
Purchases of property and equipment	102,826	155,208	164,640	57,323	23,465	96,061	-	92,018	19,369	11,398	1	0	0	1
Proceeds from sale of available-for-sale securities	-	-	-	-	-	-	-	-	-	-	-	19	-	-
Payments in connection with asset acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	198	-
Acquisition of in-process research and development	-	-	-	-	-	-	-	-	-	-	-	-	82	-
Purchase of equity securities	-	-	-	-	-	-	-	-	-	-	-	-	13	-
Net cash provided by (used in) investing activities	-3,620	-14,059,651	-7,496,801	-	-	-	-	-15,526,011	37	-5,011,398	-11	9	-294	-1
Payment of employee withholding tax related to stock-based compensation	3,410	3,410	3,410	-	-	11,265	-	4,448	-	56,197	0	0	1	1
Proceeds from Stock Options Exercised	-	-	23,500	522,000	390,351	80,251	368,185	297,563	1	758,130	4	10	3	14
Repurchase of common stock	-	-	-	-	-	-	-	-	-	-	12	7	-	-
Payment of liabilities arising from asset acquisition	-	-	-	-	-	-	-	-	-	-	-	1	13	13
Proceeds from issuance of common stock	-	43	-	-	-	-	-	-	-	-	-	-	-	141
Payment of fees in connection with issuance of common stock	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by (used in) financing activities	37	52	70	-	-	-	-	293,115	1	701,933	-8	2	-11	141
Net increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-	-	73	41	41	127	-161	380
Income Taxes Paid	-	-	-	-	-	-	-	-	-	3	3	8	50	68
Cash paid for interest	-	-	-	-	-	-	-	-	-	-	-	-	1	1
Operating lease liabilities arising from obtaining right-of-use assets	-	-	-	-	-	-	-	-	-	-	3	-	-	-
Liabilities arising from asset acquisition	-	-	-	-	-	-	-	-	-	-	-	28	2	-